New research and growing regulatory pressure around microplastics are accelerating interest in alternative materials, with seaweed emerging as a promising resource. Scientists and entrepreneurs in the UK are developing new biomaterials that could replace synthetic polymers used in cosmetics and pharmaceuticals. Yet there is increasing concern that, without stronger commercial support, these innovations could be scaled elsewhere.
Microplastics are now recognised as one of the most persistent forms of pollution in modern environments. These particles originate from many sources, including the synthetic polymers used in everyday products to stabilise medicines and give cosmetics their texture. As regulators move to restrict the use of such materials, industries are searching for substitutes that can perform the same functions without leaving lasting environmental residues.
The European Union is preparing to introduce wide restrictions on many of these polymers from 2027. That timeline is pushing companies and researchers to accelerate work on alternatives that can maintain product stability and quality while reducing reliance on petroleum based materials. Among the most promising candidates are biomaterials derived from marine resources.
One line of research began at Edinburgh Napier University, where scientists investigated an overlooked by product from seaweed processing. The work eventually led to the creation of Mercel, a spin out company focused on developing new biomaterials from this resource.
Researchers discovered that the residual seaweed biomass contains cellulose that can be extracted with lower environmental impact than traditional wood pulp processes. At the nanoscale, these fibres form stable gels that can replace certain polymers currently used in consumer goods and medicines. The materials offer similar performance while reducing the need for synthetic plastics.
The potential extends beyond a single product category. Seaweed grows quickly and does not require freshwater, fertilisers or arable land. When cultivated responsibly, it can also contribute to healthier coastal ecosystems and support marine biodiversity.
These qualities have placed seaweed at the centre of interest in the emerging bioeconomy. The material could support new supply chains for renewable ingredients in pharmaceuticals, cosmetics and advanced materials. For coastal regions, it could also provide new economic activity linked to cultivation, harvesting and processing.
The UK holds several advantages in this area. Scotland in particular has extensive coastlines suitable for seaweed cultivation. Early stage farms are already appearing, supported by regional development programmes and new approaches to sourcing naturally deposited seaweed from beaches.
Despite these strengths, commercial momentum has been uneven. Countries with established seaweed industries and more confident investment cultures are moving faster to build production capacity. The United States is already exploring large scale manufacturing and forming partnerships across the biomaterials sector.
India is also showing strong interest. With a large pharmaceutical manufacturing base, discussions around new biomaterials often focus on production scale and market opportunity. In these environments, technical barriers are treated as challenges to overcome rather than reasons to delay development.
This contrast raises questions about whether the UK can translate its scientific work into domestic economic value. The country has a long record of producing discoveries that reshape global industries, only to see the commercial benefits realised elsewhere.
Advances in DNA sequencing, for example, began in the UK but were developed into global businesses in other markets. Similar patterns have appeared across several technology sectors where early research leadership did not translate into industrial scale activity.
Seaweed based biomaterials do not have to follow that trajectory. Aligning policy, investment and industrial strategy could help retain the value created by British research. That would require clearer support for early stage manufacturing and supply chain development.
The economic opportunity extends beyond materials science. Seaweed cultivation could support new jobs in coastal communities while creating a domestic supply of marine biomass for high value applications. It also positions the UK within a wider global shift away from microplastics and synthetic polymers.
Industry and research leaders will examine these questions at the Industrial Biotechnology Innovation Centre annual conference in Glasgow. The event will bring together companies, researchers and policymakers to discuss how Scotland and the wider UK can expand their bioeconomy.
Many of the technical building blocks already exist. Research institutions are producing new materials and early stage companies are beginning to commercialise them. The remaining challenge lies in translating laboratory success into industrial scale production.
If that transition happens within the UK, the country could play a leading role in the development of marine biomaterials. If not, the technologies may still reach global markets but the manufacturing and economic value may emerge elsewhere.
Seaweed resources along the British coastline represent a natural starting point for this work. The question now is whether the country will commit to building the industries that can grow from them.
